Skip to main content

Part of cannabis and small business and retail

Marijuana producer Aphria Inc. has signed a letter of intent to supply a company in Paraguay with medical cannabis.

Under the agreement, Aphria will supply Insumos Medicos S.A., a pharmaceutical manufacturing, import and distribution company.

Aphria says Insumos will undertake the registration of the Canadian company’s products in Paraguay and the appropriate licensing for the import of medical cannabis.

Story continues below advertisement

Paraguay will become the Ontario company’s third market in Latin America, following Argentina and Colombia.

Aphria has been under pressure in recent days after short-sellers alleged the company bought assets in Colombia, Argentina and Jamaica at “vastly inflated prices.”

The company has denied the allegations, but it has appointed a special committee to review the acquisitions.

Available now: Cannabis Professional, the authoritative e-mail newsletter tailored specifically for professionals in the rapidly evolving cannabis industry. Subscribe now.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Discussion loading ...

Cannabis pro newsletter